Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Chemours Rose as Much as 13.3% Today

By Maxx Chatsko – Nov 5, 2019 at 2:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The titanium dioxide manufacturer performed well in the third quarter despite a challenging market environment.

What happened

Shares of The Chemours Company (CC 2.23%) jumped over 13% today after the company reported third-quarter 2019 operating results. The engineered materials manufacturer reported solid results despite a difficult global environment for its main product, titanium dioxide. In fact, the business topped Wall Street expectations for revenue ($1.39 billion actual vs. $1.37 billion expected) and met the consensus estimate for adjusted earnings per share (EPS) of $0.59.

The ability to meet expectations in the face of global trade tensions and a slowing global economy -- both of which place heavy burdens on commodity-driven businesses such as Chemours -- has the stock sitting comfortably higher than the three-year lows set just months ago. Investors may not want to label it a value stock just yet, however.

As of 1:18 p.m. EST, the stock had settled to a 10.2% gain.

A pair of hands holding up stacks of coins

Image source: Getty Images.

So what

While investors are happy with the third-quarter performance, it's all relative. The business is still contracting compared to last year, as prices and demand for titanium dioxide have fallen. Revenue in the first nine months of 2019 stood at $4.17 billion, down from $5.17 billion in the year-ago period. Income before taxes fell 67% in the comparison period.

Knowing that the worst macroeconomic headwinds are still to come, Chemours is moving quickly to improve operating efficiency and maintain an acceptable level of profitability in the face of mounting challenges. The company decided to shut down its methylamines and methylamides business (read: commodity products) and is reviewing ways to potentially restructure its remaining portfolios.

Additionally, and perhaps more important for investors with a long-term mindset, Chemours is eager to stabilize its titanium dioxide segment and bolster its controversial fluoroproducts business. Those efforts include being a responsible steward of global supply for titanium dioxide, and capturing more value from the specific applications enabled by its fluoropolymers.

Now what

The latest quarterly results indicate that Chemours is doing its best to navigate a number of macroeconomic headwinds, especially those related to international trade. But investors can't overlook the risks posed by uncertainty in trade, the inevitable slowdown of the cyclical and commodity-driven titanium dioxide industry, or the potential legal fallout from the company's fluoroproducts business.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Chemours Stock Quote
$27.91 (2.23%) $0.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.